EIF4B and Alzheimer disease: Last, the possibility to use gene therapy protocols (i.e., nasal delivery of viral particles) or specific delivery systems (conjugation with nanoparticles) aimed at delivering shRNAs against CK2 or eIF4B in a cell specific and temporally restricted way could open new interesting possibilities to selectively target this pathogenetic processes in AD.